Recombinant Human PCSK9 (D374Y,C-6His)

Description

EnkiLife provides the Recombinant Human PCSK9 (D374Y,C-6His) protein,aslo know as Proprotein Convertase Subtilisin/Kexin Type 9,Neural Apoptosis-Regulated Convertase 1,NARC-1,Proprotein Convertase 9,PC9,Subtilisin/Kexin-Like Protease PC9,PCSK9,NARC1, which features high purity, high activity, and high stability. It can be applied in scientific research, biopharmaceuticals, and other fields.Purity:Greater than 95% as determined by reducing SDS-PAGE;Endotoxin Level:<1 EU/µg as determined by LAL test.;Construction:Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9 is produced by our Mammalian expression system and the target gene encoding Gln31-Gln692 (Asp374Tyr,Val474Ile, Gly504Arg, Gly670Glu) is expressed with a 6His tag at the C-terminus.Accession:Q8NBP7. Expression Host:Human Cells.Species:Human.Predicted Molecular Mass:15-18&60-80 KDa. Background:Recombinant Human Proprotein Convertase Subtilisin/Kexin Type 9/PCSK9 (D374Y) is a gain of function mutant of human PCSK9 protein. Human PCSK9 is a secretory subtilase belonging to the proteinase K subfamily. PCSK9 is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the ER, the pro domain and mature chain are secreted together through noncovalent interactions. PCSK9 binds with low-density lipoprotein receptor (LDLR) and it plays a major regulatory role in cholesterol homeostasis. Inhibition of PCSK9 function by preventing PCSK9/LDLR interaction is currently being explored as a means of lowering cholesterol levels. PCSK9 also binds to apolipoprotein receptor 2 (ApoER2), and play a role in the neural development.